The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Open accessAbstract
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation. Genetic or pharmacological inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs. These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibition of the FGFR signaling pathway reduces ERK and mTOR activation, whereas AXL inhibition attenuates the activation of PI3K pathway [43, 136–139].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [43]
In the citing paper
“High feedback activation of the FGFR/AXL signaling pathway was found in mesenchymal cells.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [43]
In the citing paper
“In the context of an EMT, AXL upregulation appears as a novel mechanism of acquired EGFR-TKI resistance in EGFR-mutant NSCLCs.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Therefore, an EMT-associated transcriptional programme involving upregulation of vimentin may, in part, drive AXL overexpression in EGFR-mutant lung cancer cells with acquired EGFR-TKI resistance.40”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Pharmacological inhibition of AXL significantly decreased the proliferative and invasive abilities of cancer cells and increased their chemosenstivity through inhibition of AKT and MAPK pathways.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Rare EGFR point mutations (<10% of patients) that result in resistance include Asp761Tyr,39 Thr854Ala,40 and Leu747Ser. The mechanism (or mechanisms) underlying resistance conferred by these mutations is still unclear.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“Recently, an integrated analysis in human EGFR-mutant NSCLC models and in a large clinical cohorts of paired NSCLC specimens from EGFR-TKI-treated patients demonstrated an upregulation of AXL tyrosine kinase receptor or of its ligand, GAS6, in resistant samples.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [40]
In the citing paper
“We observed an AXL mutation in one case with acquired T790M/C797S (Pt. 12 Supple Table 2)[24], suggesting association with EMT.”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [24]
In the citing paper
“AXL inhibition has been reported to sensitize drug-resistant mesenchymal tumor cells to anticancer agents, including antimitotic agents, epidermal growth factor receptor (EGFR) inhibitors, and PI3K inhibitors”
From Hypoxic control of metastasis (2016) · cites this paper as [84]
In the citing paper
“Finally, in erlotinib-resistant EGFR mutant lung cancer cells and lapatinib-resistant HER2-amplified breast cancer cells, levels of the AXL RTK were markedly increased (Liu et al., 2009; Zhang et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Zhang et al., 2012
In the citing paper
“Targeting AXL was able to re-sensitize some of these resistant cancers to the original TKI.”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Zhang et al., 2012
In the citing paper
“In similar examples of resistance mediated by IGF-IR and AXL, inhibition of the bypass RTK in combination with the EGFR is needed to overcome resistance (Cortot et al., 2013; Guix et al., 2008; Zhang et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Zhang et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793
Self-citationVuoriluoto, K., Haugen, H., Kiviluoto, S., Mpindi, J.-P., Nevo, J., Gjerdrum, C., Tiron, C. E., Lorens, J. B., & Ivaska, J. (2010) · Oncogene · doi:10.1038/onc.2010.509 · Cited by 643
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Self-citationFAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396
Self-citationQian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 312
Azumi, N., & Battifora, H. A. (1987) · American Journal of Clinical Pathology · doi:10.1093/ajcp/88.3.286 · Cited by 303
Suda, K., Tomizawa, K., Fujii, M., Murakami, H., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318216ee52 · Cited by 283
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
Chitale, D. A., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szőke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 232
Self-citationYe, X., Li, Y., Stawicki, S. S., Couto, S. S., Eastham‐Anderson, J., Kallop, D. Y., Weimer, R. M., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 231
Brevet, M., Arcila, M. E., & Ladanyi, M. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090140 · Cited by 205
Self-citationPersonalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer
Gazdar, A. F. (2009) · New England Journal of Medicine · doi:10.1056/nejme0905763 · Cited by 177
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Linger, R. M. A., Keating, A. K., Earp, H. S., & Graham, D. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.515980 · Cited by 171
Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
Tai, K.-Y., Shieh, Y.-S., Lee, C.-S., Shiah, S., & Wu, C.-W. (2008) · Oncogene · doi:10.1038/onc.2008.57 · Cited by 170
Keating, A. K., Kim, G. K., Jones, A. E., Donson, A. M., Ware, K. E., Mulcahy, J. M., Salzberg, D. B., Foreman, N. K., Liang, X., Thorburn, A. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0707 · Cited by 148
Rosell, R., Wei, J., & Tarón, M. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.001 · Cited by 133
Self-citationDeterminants for transformation induced by the Axl receptor tyrosine kinase
Burchert, A., Attar, E. C., McCloskey, P., Fridell, Y.-W. C., & Liu, E. T. (1998) · Oncogene · doi:10.1038/sj.onc.1201865 · Cited by 65
Cited by
Sorted by citations
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citationEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Metadata
- Authors
- Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., Choi, Y. J., Choi, C.-M., Kim, S.-W., Jang, S. J., Park, Y. S., Kim, W. S., Lee, D. H., Lee, J.-S., Miller, V. A., Arcila, M., Ladanyi, M., Moonsamy, P., Sawyers, C., Boggon, T. J., Ma, P. C., Costa, C., Taron, M., Rosell, R., Halmos, B., & Bivona, T. G.
- Affiliations
- Columbia University Irving Medical Center (US)
- Asan Medical Center (KR)
- University of California, San Francisco (US)
- University Hospitals Cleveland Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Yale University (US)
- Cleveland Clinic (US)
- Institut Català d'Oncologia (ES)
- Corresponding author
- Bivona, Trever G
- ORCID
- Zhang, Zhenfeng
- Lee, Jae Cheol
- Lin, Luping
- LaFramboise, Thomas
- Wang, Xiaoqi
- Levine, Alan D
- Rho, Jin Kyung
- Choi, Yun Jung
- Choi, Chang-Min
- Jang, Se Jin
- Park, Young Soo
- Kim, Woo Sung
- Lee, Dae Ho
- Lee, Jung-Shin
- Miller, Vincent A
- Arcila, Maria
- Ladanyi, Marc
- Moonsamy, Philicia
- Sawyers, Charles
- Boggon, Titus J
- Rosell, Rafael
- Bivona, Trever G
- Venue
- Nature Genetics
- Published
- 2012-07-01
- Volume
- 44
- Issue
- 8
- Pages
- 852-860
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC3408577
- OpenAlex
- W1983774108
- Cited by
- 1,224
- References
- 29
- Citations by year
- 2026: 37 · 2025: 61 · 2024: 49 · 2023: 85 · 2022: 73 · 2021: 86 · 2020: 101 · 2019: 89 · 2018: 103 · 2017: 112 · 2016: 116 · 2015: 131 · 2014: 82 · 2013: 82 · 2012: 14
- FWCI
- 80.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T35HL007616)
- National Cancer Institute (R01CA169338, DP2CA174497, P01CA129243, K08CA154787, K08 1K08CA154787)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- AXL kinase, erlotinib resistance, EGFR-mutant lung cancer, non-small cell lung cancer, tyrosine kinase inhibitors, epithelial-mesenchymal transition, Gas6, acquired drug resistance, therapeutic target, MET kinase
- MeSH terms
- Erlotinib Hydrochloride, Axl Receptor Tyrosine Kinase, Growth Arrest-Specific Protein 6, Adult, Aged, Animals, Carcinoma, Non-Small-Cell Lung, Enzyme Activation, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Quinazolines, Signal Transduction, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Receptor Protein-Tyrosine Kinases, Xenograft Model Antitumor Assays, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Protein Kinase Inhibitors, Epithelial-Mesenchymal Transition, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
